… In all cases, the FimH antagonists were directly instilled into the … FimH antagonists exhibiting
appropriate pharmacokinetic properties for iv and oral treatment of urinary tract infections…

… FimH antagonists for both prevention and treatment of UTIs in vivo. In addition, FimH
antagonists … Whereas in the initial treatment experiments[7,8] bacteria/antagonist mixtures were …

… FimH protein, containing only the carbohydrate recognition domain. FimH is immobilized and
FimH antagonists … that were infected ex vivo with LF82, with or without FimH antagonists. In …

… FimH antagonists disclosed in the patent literature. X-ray crystallographic binding studies of
D-mannose and early FimH antagonists … orally bioavailable FimH antagonists with promising …

… of orally active small-molecule FimH antagonists and demonstrate their potential for treating
… a resistant bacterial infection. Our mannoside compounds block the FimH-mediated binding …

… in binding affinity of FimH antagonists with FimH FL and FimH LD , respectively, we studied
the binding thermodynamics of the FimH antagonists 1 and 3p for both FimH proteins by …

… Mannose-based FimH antagonists are considered new therapeutics for the treatment of
urinary tract infections (UTIs). They prevent the adhesion of uropathogenic Escherichia coli (…

… We hypothesized that the fitness advantage of expressing FimH::A62/V163 over FimH::S62/A163
throughout infection was due to differences in the ability to bind mannosylated epitopes …

… Escherichia coli ST131 causes acute urinary tract infection in female C3H/HeN mice. Scatter
plots of E. coli EC958 titers (colony-forming units [CFU]/organ) in bladders (A) and kidneys (…

Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (UPEC) affect 150
million people annually 1 , 2 . Despite effective antibiotic therapy, 30–50% of patients …